PLX164240

GSE152904: FcRIIB engagement drives agonistic activity of Fc-engineered OX40 antibody to stimulate human tumor-infiltrating T cells

• Organsim human
• Type RNASEQ
• Target gene
• Project ARCHS4

Background: OX40 (CD134) is a co-stimulatory molecule of the tumor necrosis factor receptor (TNFR) superfamily, that is currently investigated as a target for cancer immunotherapy. However, despite promising results in murine tumor models, the clinical efficacy of agonistic OX40 antibodies in treatment of cancer patients has fallen short of the high expectation in earlier stage trials.; Methods: Using lymphocytes from resected tumor, tumor-free tissue and PBMC of 4 hepatocellular and colorectal cancer patients, we performed RNA-Seq to evaluate OX40-mediated transcriptional changes in CD4+ and CD8+ human tumor-infiltrating lymphocytes (TILs).; Results: The transcriptional landscape of CD4+ and CD8+ TILs shifted towards a pro-survival, inflammatory and chemotactic profile upon treatment with OX40_v12. SOURCE: Lucia Campos Carrascosa Erasmus Medical Center